New hope for leukemia patients: experimental combo targets tough cases
NCT ID NCT07271667
Summary
This study is testing whether adding a new drug called emavusertib to an existing cancer medication (zanubrutinib) can better control chronic lymphocytic leukemia and similar blood cancers. It will enroll 108 adults who are already taking zanubrutinib but need additional treatment. Researchers will measure how well the combination eliminates cancer cells and controls the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mt Sinai Comprehensive Cancer Center
RECRUITINGMiami Beach, Florida, 33140, United States
Conditions
Explore the condition pages connected to this study.